This observational research study will involve approximately 5000 subjects with UC or CD in approximately 350 study centers located in North America and Europe. Study participants must be 18 years of age or older at the time of enrollment and will be either starting Vedolizumab or will be starting on another biologic medication for their disease. 20 of the patients will be from BAMC.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.